Nycomed names new chairman
Nycomed Amersham this month named a new chairman, sparking speculation that the company’s Norwegian influence is decreasing. Richard Lapthorne, Nycomed’s deputy chairman, will trade jobs with chairman Johan Odfjell at the conclusion of the
Nycomed Amersham this month named a new chairman, sparking speculation that the companys Norwegian influence is decreasing. Richard Lapthorne, Nycomeds deputy chairman, will trade jobs with chairman Johan Odfjell at the conclusion of the firms annual general meeting on May 6. Odfjell was appointed chairman when Nycomed and Amersham merged into a $2.5 billion drug company in October 1997 (SCAN 7/9/97 and 10/29/97). The Buckinghamshire, U.K., and Oslo, Norway, company also announced that its executive director, Tore Laerdal, will retire after the meeting.
At the time of the merger, the two companies took care to balance the new entitys executive lineup between U.K. and Norwegian officers. But industry experts wonder if the company is gradually leaning toward Buckinghamshire. Lapthorne and Odfjells switch is the latest in a series of personnel shifts in which many Norway-based executives have left the company.
Mammography Study Compares False Positives Between AI and Radiologists in DBT Screening
May 8th 2025For DBT breast cancer screening, 47 percent of radiologist-only flagged false positives involved mass presentations whereas 40 percent of AI-only flagged false positive cases involved benign calcifications, according to research presented at the recent American Roentgen Ray Society (ARRS) conference.
Study Shows No Impact of Hormone Therapy on PET/CT with 18F-Piflufolastat in PCa Imaging
May 7th 2025For patients with recurrent or metastatic prostate cancer, new research findings showed no significant difference in the sensitivity of 18F-piflufolastat PET/CT between patients on concurrent hormone therapy and those without hormone therapy.
